

Major Products

Shionogi strives constantly to provide medical professionals and patients with medicine of the best possible kind essential for protection of the health of the people.

Prescription Drugs

- **Crestor® Tablet Hyperlipidemia Treatment (*Rosuvastatin Calcium*)**
Launched April 2005

The clinical effectiveness of Crestor® for preventing atherosclerotic diseases has been confirmed by many large-scale clinical studies in Japan and overseas, such as JUPITER and COSMOS.

As a statin with an outstanding serum lipid improving effect and accumulated evidence of efficacy and safety for patients, Crestor® has earned a high evaluation among medical professionals.

Crestor® is particularly attractive due to the current evidence about the relationship between the regression of atherosclerosis and the ratio of LDL cholesterol to HDL cholesterol, "bad cholesterol/good cholesterol," and is expected to drive the statin therapy forward.



- **Irbesartan® Tablet Antihypertensive (*Irbesartan*)**
Launched July 2008

A long-acting angiotensin II receptor blocker with a superior antihypertensive effect, Irbesartan® is promoted with materials centered on the phrase "powerful and long-acting for protection." Large-scale clinical trials overseas have confirmed the beneficial renoprotective effect of Irbesartan®, which is marketed in 88 countries. Besides providing information on Irbesartan®, Shionogi is promoting greater awareness of the need to diagnose and treat chronic kidney disease (CKD) through a campaign centered on the phrase "Beat the CKD."



- **Finibax® Carbapenem Antibiotic (*Doripenem Hydrate*)**
Launched September 2005

Finibax® is a carbapenem antibacterial agent for infusion with a broad spectrum of superior antibacterial activity against various bacteria. Antibacterial activity especially against *Pseudomonas aeruginosa* is the most potent among carbapenem antibacterial agents, and it was revealed recently that Finibax® had an inhibitory action on the formation of carbapenem resistance in *Pseudomonas aeruginosa*. Finibax® is being recognized as a highly useful drug for the treatment of serious infections.



- **Pirespa® Tablet Idiopathic Pulmonary Fibrosis Treatment (*Pirfenidone*)**
Launched December 2008

Offering the effect of inhibiting pulmonary fibrosis, Pirespa® has demonstrated efficacy in the treatment of idiopathic pulmonary fibrosis, and, in December 2008, Shionogi became the first company in the world to obtain manufacturing and marketing approval of the drug for that indication. Giving top priority to ensuring patient safety, Shionogi is now marketing Pirespa® while conducting post-marketing surveillance on all the patients taking the drug.



- **Differin® Gel Acne Vulgaris Treatment (*Adapalene*)**
Launched October 2008

Differin® Gel 0.1% has been approved and launched in more than 80 countries around the world, and it is the first topical retinoid preparation to be approved for the application of treating acne vulgaris in Japan. Marketed (in Japan) since October 2008, it is being promoted by Shionogi in cooperation with Galderma KK. A fundamental element of acne vulgaris therapy, Differin® Gel is expected to improve acne patients' quality of life and satisfaction with the efficacy of their treatment. Shionogi is providing medical information to promote its appropriate use, mainly by dermatologists.



- **Claritin® Tablet, RediTabs®, Dry Syrup Allergy Treatment (*Loratadine*)**
Launched September 2002

A non-sedative antihistamine drug that is effective when taken once daily but does not cause drowsiness or affect mental concentration or learning ability, Claritin® has been confirmed to have outstanding efficacy and safety. Having already launched Claritin® 10mg tablets in September 2002 and Claritin® RediTabs® 10mg tablets in November 2004, Shionogi further expanded the Claritin® lineup with the January 2008 launch of Claritin® Dry Syrup 1%, thereby creating Japan's first line of antihistamines to include three different formulation types. By expanding the number of formulation alternatives, this initiative was designed to enable the Claritin® family to meet the needs of a still-broader range of age-groups.



- **OxyContin® Cancer Pain Analgesic OxyContin® Tablets (Oxycodone Hydrochloride Hydrate)**

Launched July 2003

- **OxiNorm® Powder 0.5% (Oxycodone Hydrochloride Hydrate)**

Launched February 2007

The World Health Organization and other authorities recommend treating cancer-related pain with oral drugs that include immediate-release and extended-release formulations of the same active ingredient, with the same administration route. Shionogi strongly agrees with this recommendation, as is reflected in the Company's product line—Shionogi's cancer-related pain treatment products include extended-release OxyContin® Tablets and immediate-release OxiNorm® Powder 0.5%. Shionogi does its utmost to appropriately promote these products in a manner that enables patients to be liberated from pain so they can live their lives calmly and peacefully.



OTC Drugs

Amid the steady increase of demographic graying in Japan, progress is being made in efforts to promote the greater awareness of the benefits of self-medication. Shionogi is working to expand its healthcare business by providing the products customers need.

- **Sedes® Analgesic Antipyretics**

The four items in Shionogi's Sedes® line of analgesic antipyretics allow users to choose the most appropriate product for a given situation. In spring 2009, the Company renovated the packaging design for these products. These include New Sedes®, designed for household use in treating minor fevers and headaches; Sedes®-Hi, which is effective for treating painful headaches and toothaches that demand urgent relief measures; Sedes® V, which relieves the pain of stiff shoulders and related headaches; and Sedes® Cure, an effective means of countering menstrual pains and sore throats.



- **Popon® Vitamin Compounds**

Popon® S is a well-balanced comprehensive vitamin supplement that provides elements that people with modern lifestyles tend to lack, including eight vitamins as well as calcium and magnesium. Many people take it daily as a means of establishing a strong foundation for good health. The Popon® line also includes Popon® C White, which contains vitamin C with L-cysteine to help moderate blemishes and freckles, and Shionogi is preparing for the September 2009 launch of Popon® B Fresh, a new vitamin B₁-centered product designed to help relieve muscular fatigue.



Diagnostics

Shionogi aims to contribute to better human health by providing a broad range of products for therapeutic as well as diagnostic applications. In the cardiovascular/metabolism domain, Shionogi supplements such therapeutic products as Crestor® and Irbetan® with reagent products used to measure blood levels of brain natriuretic peptide (BNP). Similarly, in the immune system/allergy domain, Shionogi complements such therapeutic products as Claritin® and Rinderon® with reagent products used to measure histamine and thymus and activation-regulated chemokine (TARC).

- **Allerport® TARC Th2 Chemokine/TARC Kit**

Launched February 2008

Allerport® TARC is used to measure serum levels of TARC, which rise in step with atopic dermatitis symptoms. Thus, this diagnostic product enables the evaluation of the severity of atopic dermatitis symptoms.



- **MI02 Shionogi BNP (Human BNP Kit) and MI02 Shionogi BNP Immunoluminescence Measurement Unit**

Launched December 2004

- **Shionospot® BNP (Human BNP Kit) and Shionospot® Reader Portable Immunoluminescence Analysis Unit**

Launched September 2006

Because blood levels of BNP will rise when heart functions are even lightly impaired, they are a useful indicator for reference when diagnosing and assessing cardiac insufficiency. Recent therapeutic guidelines cite testing of BNP blood levels as a useful means of screening people with hypertension for signs of cardiac insufficiency. MI02 Shionogi BNP and Shionospot® BNP are reagents used to measure the BNP level, while MI02 and Shionospot® Reader are electronic units that use those reagents to perform actual measurements.

